December 21, 2018
Novocure to Participate in the 37th Annual J.P. Morgan Healthcare Conference
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 9, 2019, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. He is scheduled to present at 2:30… Read More
learn more
December 21, 2018
Novocure to Participate in the 37th Annual J.P. Morgan Healthcare Conference
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 9, 2019, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. He is scheduled to present at 2:30… Read More
learn more
December 17, 2018
Novocure and the AACR Announce Four Inaugural Research Grants to Promote and Support Innovative Research on Tumor Treating Fields
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) and the American Association for Cancer Research (AACR) announce four inaugural Tumor Treating Fields research grants. The grants represent a joint effort to promote and support innovative research on Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric… Read More
learn more
December 17, 2018
Novocure and the AACR Announce Four Inaugural Research Grants to Promote and Support Innovative Research on Tumor Treating Fields
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) and the American Association for Cancer Research (AACR) announce four inaugural Tumor Treating Fields research grants. The grants represent a joint effort to promote and support innovative research on Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric… Read More
learn more
December 6, 2018
Sub-Group Analysis of Novocure’s EF-14 Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Published in Journal of Neuro-Oncology Demonstrating More Time on Optune® Predicted Increased Survival
Patients who used Optune more than 90 percent of the time experienced a median overall survival of 24.9 months Monthly usage was a predictor of survival, independent of other prognostic factors such as Karnofsky Performance Score, age, or MGMT methylation status ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR)… Read More
learn more
December 6, 2018
Sub-Group Analysis of Novocure’s EF-14 Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Published in Journal of Neuro-Oncology Demonstrating More Time on Optune® Predicted Increased Survival
Patients who used Optune more than 90 percent of the time experienced a median overall survival of 24.9 months Monthly usage was a predictor of survival, independent of other prognostic factors such as Karnofsky Performance Score, age, or MGMT methylation status ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR)… Read More
learn more
